1 2026

The complement system contributes to the immunosuppressive microenvironment of uveal melanoma

Zherka I, Kalirai H, Majorova D, Coupland SE, Olcina MM

Journal of Translational Medicine

2026 Mar 9 DOI: 10.1186/s12967-026-07910-y PMID: 41803879

2 2026

Tissue resident memory T cells populate the human uveal tract

Foers AD, Reekie IR, Wickramasinghe LC, Ward A, Buckley TM, Attar M, Aguilar-Munoa S, Pilapil Q, Abdalla Elsayed ME, Pledger S, Bhalla A, Hedley R, Hill S, Windell D, Barton K, Masood I, Lim KS, Coles MC, Sherlock JP, Dick AD, Coupland SE, Sansom SN, Copland DA, Buckley CD, Sharma SM; ORBIT Consortium

Scientific Reports

2026 Apr 3;16(1):11330 DOI: 10.1038/s41598-025-33444-2 PMID: 41932938

3 2026

Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study

Kersten MJ, Dreyling M, Linton KM, Chitu D, Zwezerijnen GJC, Tonino SH, Kap M, Liu R, Van Hooije C, Chamuleau MED, Visser HPJ, De Jongh E, Marijt EAF, Leys MBL, Bilgin YM, Dürig J, McKay P, Snijders T, Pettitt A, Minnema MC, Prange-Krex G, Cuijpers MLH, Bohmer LH, Tick LW, Florschutz A, Silbermann M, Fijnheer R, Beeker A, Tolboom N, Mitea C, Arens AIJ, Wiegers SE, Heymans MW, Klapper W, Coupland SE, De Jong D, Doorduijn JK, Zijlstra JM

Haematologica

DOI: 10.3324/haematol.2025.300152 PMID: 41988778